Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tums takes on competition

This article was originally published in The Tan Sheet

Executive Summary

Pepcid AC "takes, like, 40 minutes to start working," according to female diner patron in Tums spot that launched Sept. 30 and focuses on Tums' quick action. Diner cook states "Tums starts neutralizing acid fast," tells male patron using Prilosec OTC, "Read the label, that can take one to four days to kick in." Referring to delayed-release PPI, cook notes "it should say delayed relief." Pepcid AC-marketer Johnson & Johnson/Merck has clashed with Tums marketer GlaxoSmithKline over ad claims through National Advertising Division (1"The Tan Sheet" Aug. 6, 2001, p. 4)...

You may also be interested in...



Heartburn ad wars

Currently airing fifteen-second Maximum Strength Pepcid AC spot depicts a pen scrawling on the heartburn medication's labeling so that the "P" in Pepcid becomes "Rx." An accompanying voiceover says: "Now there's a prescription-strength Pepcid AC for your heartburn. New Maximum Strength Pepcid AC. With twice the strength of the original. Pepcid. Just one...and heartburn's done." In the ad, Johnson & Johnson compares the line extension to original Pepcid AC without making comparisons to competing products such as Procter & Gamble's Prilosec OTC. Tums manufacturer GlaxoSmithKline, meanwhile, is taking the head-to-head approach by making comparisons to both Pepcid AC and Prilosec OTC in its advertising (1"The Tan Sheet" Oct. 6, 2003, In Brief)...

Rolaids Line Expands Into Gas Relief With Multi-Symptom Extension

Pfizer is positioning new Rolaids Multi-Symptom line extension as handling gas as well as heartburn in comparison to GlaxoSmithKline's Tums in spots that broke November 17

J&J/Merck "Completes" Sweep Of NAD, Court Ad Challenges

Future Tums Ultra ads should not compare the product's acid neutralization capacity with that of Pepcid Complete, the National Advertising Division of the Council of Better Business Bureaus says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel